Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Rationale and clinical development of CD40 agonistic antibodies for cancer immunotherapy

Enell Smith, Karin LU ; Deronic, Adnan LU ; Hägerbrand, Karin LU ; Norlén, Per LU and Ellmark, Peter LU (2021) In Expert Opinion on Biological Therapy 21(12). p.1635-1646
Abstract

Introduction: CD40 signaling activates dendritic cells leading to improved T cell priming against tumor antigens. CD40 agonism expands the tumor-specific T cell repertoire and has the potential to increase the fraction of patients that respond to established immunotherapies. Areas covered: This article reviews current as well as emerging CD40 agonist therapies with a focus on antibody-based therapies, including next generation bispecific CD40 agonists. The scientific rationale for different design criteria, binding epitopes, and formats are discussed. Expert opinion: The ability of CD40 agonists to activate dendritic cells and enhance antigen cross-presentation to CD8+ T cells provides an opportunity to elevate response rates... (More)

Introduction: CD40 signaling activates dendritic cells leading to improved T cell priming against tumor antigens. CD40 agonism expands the tumor-specific T cell repertoire and has the potential to increase the fraction of patients that respond to established immunotherapies. Areas covered: This article reviews current as well as emerging CD40 agonist therapies with a focus on antibody-based therapies, including next generation bispecific CD40 agonists. The scientific rationale for different design criteria, binding epitopes, and formats are discussed. Expert opinion: The ability of CD40 agonists to activate dendritic cells and enhance antigen cross-presentation to CD8+ T cells provides an opportunity to elevate response rates of cancer immunotherapies. While there are many challenges left to address, including optimal dose regimen, CD40 agonist profile, combination partners and indications, we are confident that CD40 agonists will play an important role in the challenging task of reprogramming the immune system to fight cancer.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; and
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
agonist, antibodies, CD40, immuno-oncology
in
Expert Opinion on Biological Therapy
volume
21
issue
12
pages
1635 - 1646
publisher
Ashley Publications
external identifiers
  • scopus:85108182920
  • pmid:34043482
ISSN
1471-2598
DOI
10.1080/14712598.2021.1934446
language
English
LU publication?
yes
id
4b2117f9-883a-490c-a775-29db33ae59ad
date added to LUP
2021-07-13 14:06:52
date last changed
2024-12-15 09:14:09
@article{4b2117f9-883a-490c-a775-29db33ae59ad,
  abstract     = {{<p>Introduction: CD40 signaling activates dendritic cells leading to improved T cell priming against tumor antigens. CD40 agonism expands the tumor-specific T cell repertoire and has the potential to increase the fraction of patients that respond to established immunotherapies. Areas covered: This article reviews current as well as emerging CD40 agonist therapies with a focus on antibody-based therapies, including next generation bispecific CD40 agonists. The scientific rationale for different design criteria, binding epitopes, and formats are discussed. Expert opinion: The ability of CD40 agonists to activate dendritic cells and enhance antigen cross-presentation to CD8<sup>+</sup> T cells provides an opportunity to elevate response rates of cancer immunotherapies. While there are many challenges left to address, including optimal dose regimen, CD40 agonist profile, combination partners and indications, we are confident that CD40 agonists will play an important role in the challenging task of reprogramming the immune system to fight cancer.</p>}},
  author       = {{Enell Smith, Karin and Deronic, Adnan and Hägerbrand, Karin and Norlén, Per and Ellmark, Peter}},
  issn         = {{1471-2598}},
  keywords     = {{agonist; antibodies; CD40; immuno-oncology}},
  language     = {{eng}},
  number       = {{12}},
  pages        = {{1635--1646}},
  publisher    = {{Ashley Publications}},
  series       = {{Expert Opinion on Biological Therapy}},
  title        = {{Rationale and clinical development of CD40 agonistic antibodies for cancer immunotherapy}},
  url          = {{http://dx.doi.org/10.1080/14712598.2021.1934446}},
  doi          = {{10.1080/14712598.2021.1934446}},
  volume       = {{21}},
  year         = {{2021}},
}